Definition

A preparation of autologous T lymphocytes that have been genetically modified to express a chimeric antigen receptor (CAR) targeting the tumor-associated antigen (TAA) B-cell antigen receptor complex-associated protein beta chain (CD79b; B-cell-specific glycoprotein B29), with potential immunostimulating and antineoplastic activities. Upon administration, autologous anti-CD79b CAR-T cells JV-213 target and bind to CD79b-expressing tumor cells, thereby inducing selective toxicity in CD79b-expressing tumor cells. CD79b, a critical receptor for successful B-cell development and part of the B-cell receptor (BCR) signaling complex, is widely expressed in certain subtypes of B-cell lymphomas.